Sara Mainardi

the netherlands cancer institute

H指数:13

被引数:1,584

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer

SHERPA试验：一项I期研究，探讨SHP2抑制剂RMC-4630与ERK抑制剂LY3214996联合治疗KRAS突变型胰腺癌、非小细胞肺癌和结直肠癌患者的疗效

European Journal of Cancer

IF7.1

2026-05-060

PRE

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer

Journal of Experimental & Clinical Cancer Research

IF12.8

2026-01-220

OAAI

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

CANCER DISCOVERY

IF33.3

2024-03-266

OAAI

Dias, Matheus Henrique; Friskes, Anoek; Wang, Siying; Neto, Joao M. Fernandes; van Gemert, Frank; Mourragui, Soufiane; Papagianni, Chrysa; Kuiken, Hendrik J.; Mainardi, Sara; Alvarez-Villanueva, Daniel; Lieftink, Cor; Morris, Ben; Dekker, Anna; van Dijk, Emma; Wilms, Lieke H. S.; da Silva, Marcelo S.; Jansen, Robin A.; Mulero-Sanchez, Antonio; Malzer, Elke; Vidal, August; Santos, Cristina; Salazar, Ramon; Wailemann, Rosangela A. M.; Torres, Thompson E. P.; De Conti, Giulia; Raaijmakers, Jonne A.; Snaebjornsson, Petur; Yuan, Shengxian; Qin, Wenxin; Kovach, John S.; Armelin, Hugo A.; te Riele, Hein; van Oudenaarden, Alexander; Jin, Haojie; Beijersbergen, Roderick L.; Villanueva, Alberto; Medema, Rene H.; Bernards, Rene

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse

CELL REPORTS MEDICINE

IF10.6

2024-03-018

OAAI

Small- molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS- mutant cancers

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2024-02-202

OAAI

Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

PRE

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

密码子特异性KRAS突变预测转移性结直肠癌中三氟尿苷/替匹拉西的生存益处

NATURE MEDICINE

IF50

2023-03-0244

OAAI

van de Haar, Joris; Ma, Xuhui; Ooft, Salo N.; van der Helm, Pim W.; Hoes, Louisa R.; Mainardi, Sara; Pinato, David J.; Sun, Kristi; Salvatore, Lisa; Tortora, Giampaolo; Zurlo, Ina Valeria; Leo, Silvana; Giampieri, Riccardo; Berardi, Rossana; Gelsomino, Fabio; Merz, Valeria; Mazzuca, Federica; Antonuzzo, Lorenzo; Rosati, Gerardo; Stavraka, Chara; Ross, Paul; Rodriquenz, Maria Grazia; Pavarana, Michele; Messina, Carlo; Iveson, Timothy; Zoratto, Federica; Thomas, Anne; Fenocchio, Elisabetta; Ratti, Margherita; Depetris, Ilaria; Cergnul, Massimiliano; Morelli, Cristina; Libertini, Michela; Parisi, Alessandro; De Tursi, Michele; Zanaletti, Nicoletta; Garrone, Ornella; Graham, Janet; Longarini, Raffaella; Gobba, Stefania Maria; Petrillo, Angelica; Tamburini, Emiliano; La Verde, Nicla; Petrelli, Fausto; Ricci, Vincenzo; Wessels, Lodewyk F. A.; Ghidini, Michele; Cortellini, Alessio; Voest, Emile E.; Valeri, Nicola

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

SHP2和mTOR抑制剂的合理组合治疗肝细胞癌

MOLECULAR ONCOLOGY

IF4.5

2023-02-097